Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor Profile

Executive Summary: Anlotinib hydrochloride is a novel small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1, with nanomolar potency in endothelial cell migration and tube formation assays (source: Gene 2018). It displays superior anti-angiogenic efficacy compared to sunitinib, sorafenib, and nintedanib under equivalent in vitro conditions (source: Gene 2018). Pharmacokinetic studies reveal high plasma protein binding (93–97%) and good oral bioavailability in preclinical species (source: APExBIO product_spec). The compound shows no significant cytotoxicity at research-relevant concentrations (≤1 μM) (source: Gene 2018). Safety data indicate a high median lethal dose and no major organ toxicity (source: APExBIO product_spec).

Biological Rationale

Angiogenesis, the development of new blood vessels from pre-existing vasculature, is essential for tumor growth and metastasis. Tumors secrete pro-angiogenic cytokines such as VEGF, PDGF-BB, and FGF-2 to induce migration and tube formation in endothelial cells, supporting neovascularization and cancer progression (source: Gene 2018). Pharmacological inhibition of angiogenic pathways is a validated approach in cancer research, with multiple clinical agents demonstrating efficacy in diverse tumor types.

Mechanism of Action of Anlotinib hydrochloride

Anlotinib hydrochloride, supplied by APExBIO (SKU: C8688), is a multi-target tyrosine kinase inhibitor that selectively suppresses VEGFR2, PDGFRβ, and FGFR1 (source: product_spec). The compound blocks ligand-induced phosphorylation of these receptors, thereby inhibiting downstream ERK signaling. This results in potent suppression of endothelial cell migration and capillary-like tube formation, critical steps in angiogenesis (source: Gene 2018). Mechanistically, anlotinib's inhibition of ERK pathway activation distinguishes its anti-angiogenic effect profile and contributes to its anti-proliferative action in tumor models.

Evidence & Benchmarks

• Anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced migration of EA.hy 926 endothelial cells in a concentration-dependent manner, with IC₅₀ values of 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1 (source: Gene 2018).
• In vitro capillary tube formation assays show anlotinib achieves superior inhibition compared to sunitinib, sorafenib, and nintedanib under identical conditions (source: Gene 2018).
• No significant cytotoxicity observed in EA.hy 926 cells at concentrations up to 1 μM, supporting its suitability for functional endothelial assays (source: Gene 2018).
• Pharmacokinetic data: oral bioavailability 28–58% (rats), 41–77% (dogs); plasma protein binding 93–97%; terminal half-life 5.1 ± 1.6 h (rats), 22.8 ± 11.0 h (dogs); extensive tissue distribution including CNS (source: product_spec).
• Median lethal dose (LD₅₀) in 14-day oral studies is 1735.9 mg/kg, with no significant liver, kidney, bone marrow, reproductive, or genetic toxicity (source: product_spec).

For expanded mechanistic insights and translational frameworks, see "Anlotinib Hydrochloride: Breaking Boundaries in Tumor Ang...", which explores strategic deployment in advanced cancer research. This present article clarifies quantitative benchmarks and workflow integration details not covered in earlier discussions.

For additional perspectives on anti-angiogenic mechanisms, "Anlotinib Hydrochloride: Unveiling the Future of Multi-Ta..." provides an in-depth look at translational potential, while the current article updates with the latest comparative efficacy data and safety benchmarks.

Applications, Limits & Misconceptions

Anlotinib hydrochloride is validated for use in in vitro endothelial cell migration inhibition, capillary tube formation assays, and in vivo angiogenesis models. Its low cytotoxicity and high selectivity make it suitable for functional assays at concentrations ≤1 μM (source: Gene 2018). Extensive tissue distribution and blood-brain barrier penetration enable exploration in CNS tumor models (source: product_spec).

Common Pitfalls or Misconceptions

• Anlotinib is not a general cytotoxin and does not induce significant cell death at standard research concentrations (≤1 μM); its primary mode is anti-angiogenic (source: Gene 2018).
• The compound is not suitable for therapeutic administration in humans outside of research contexts; use is for laboratory research only (source: product_spec).
• While effective against VEGFR2, PDGFRβ, and FGFR1, activity against unrelated kinase families is unproven and should not be assumed (source: Gene 2018).
• Some in vitro CYP3A4 and CYP2C9 inhibition occurs, but clinically relevant drug-drug interactions are unlikely at research concentrations (source: product_spec).
• Effects in non-angiogenic disease models are not established and require independent validation (workflow_recommendation).

For deeper experimental design considerations, "Anlotinib Hydrochloride: A Multi-Target Tyrosine Kinase I..." focuses on troubleshooting and protocol optimization, whereas this article emphasizes the evidence hierarchy and quantitative limits.

Workflow Integration & Parameters

Protocol Parameters

• Endothelial cell migration assay | IC₅₀: 5.6 ± 1.2 nM (VEGFR2) | EA.hy 926 cells | Quantifies direct anti-migratory action | DOI
• Capillary tube formation assay | IC₅₀: 8.7 ± 3.4 nM (PDGFRβ), 11.7 ± 4.1 nM (FGFR1) | EA.hy 926 cells | Measures inhibition of pro-angiogenic morphogenesis | DOI
• Functional assays | ≤1 μM | EA.hy 926 and similar endothelial cell lines | Ensures no significant cytotoxicity | DOI
• Pharmacokinetics | Oral bioavailability: 28–58% (rat), 41–77% (dog); plasma protein binding: 93–97% | Preclinical PK/ADME | Supports in vivo dosing, tissue targeting analysis | product_spec
• Storage | -20°C | All research settings | Preserves compound stability | product_spec
• Workflow suggestion: For combinatorial screening, start with 10× below the lowest reported IC₅₀ to avoid off-target effects | Applies to multi-agent platforms | Reduces false positives | workflow_recommendation

Conclusion & Outlook

Anlotinib hydrochloride stands out as a next-generation anti-angiogenic small molecule for cancer research, with robust selectivity and potency toward VEGFR2, PDGFRβ, and FGFR1, and favorable pharmacokinetics and safety profile (source: Gene 2018, APExBIO). The superior performance over established clinical agents reinforces its utility in preclinical angiogenesis and tumor proliferation models. Ongoing research will further clarify its translational potential, especially in CNS-penetrant and multi-kinase-targeted cancer strategies. Researchers are encouraged to reference the C8688 kit from APExBIO for standardized workflows and consult peer-reviewed protocols for optimal integration into advanced cancer model systems.